[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628747":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":19,"locations":10,"responsibleParty":25,"collaborators":10,"id":27,"slug":28,"hasResults":29,"nctId":30,"briefTitle":31,"officialTitle":32,"acronym":33,"eligibilityCriteria":34,"healthyVolunteers":29,"sex":35,"minAge":36,"maxAge":37,"enrollmentInfo":38,"targetDuration":10,"studyType":41,"phases":10,"briefSummary":42,"conditions":43,"keywords":45,"overallStatus":49,"whyStopped":10,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":10},{"fullName":5,"class":6},"Novartis","INDUSTRY",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"ARNi Cohort",null,"Patients with a clinical diagnosis of hypertension who initiate or switch to ARNi (sacubitril\u002Fvalsartan) treatment.",{"label":13,"type":10,"description":14,"interventionNames":10},"Monotherapy Cohort","Patients with a clinical diagnosis of hypertension who initiate antihypertensive monotherapy including an ACE inhibitor, ARB, or CCB.",[16],{"name":17,"affiliation":17,"role":18},"Novartis Pharmaceuticals","STUDY_DIRECTOR",[20,24],{"name":17,"role":21,"phone":22,"phoneExt":10,"email":23},"CONTACT","+41613241111","novartis.email@novartis.com",{"name":17,"role":21,"phone":10,"phoneExt":10,"email":10},{"type":26,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100628747","a-real-world-study-of-the-effectiveness-of-angiotensin-receptor-neprilysin-inhibitor-therapy-in-hypertensive-patients-in-the-united-arab-emirates-100628747",false,"NCT07465666","A Real-world Study of the Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor Therapy in Hypertensive Patients in the United Arab Emirates","Real-world Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor (ARNi) Therapy in Lowering Blood Pressure in Hypertensive Patients in the United Arab Emirates","REAL-HTN","Inclusion criteria:\n\n1. Adult male or female patients (≥18 years).\n2. Patients with physician-diagnosed hypertension (as defined by international guidelines including the American Heart Association\u002FAmerican College of Cardiology \\[AHA\u002FACC\\] guidelines and\u002For the 2024 European Society of Cardiology \\[ESC\\] guidelines).\n3. Patients with documented office blood pressure ≥130\u002F80 mmHg prior to initiating treatment (ARNi or monotherapy) or transitioning from monotherapy to ARNi.\n4. Patients who are either antihypertensive therapy naïve or currently receiving antihypertensive monotherapy (ACE inhibitor\u002FARB\u002FCCB) with a physician-directed requirement to transition to ARNi.\n\n   Note: Patients who transition from one monotherapy to another during the study are not eligible for inclusion.\n5. Patients willing to provide written informed consent to participate in the study.\n\nExclusion criteria:\n\n1. Patients with malignant or severe hypertension (systolic blood pressure \\[SBP\\] ≥180 mmHg, diastolic blood pressure \\[DBP\\] ≥110 mmHg) at baseline.\n2. Patients with secondary causes of hypertension, as determined by the treating physician.\n3. Patients with a history of, or at risk of developing, angioedema.\n4. Patients with evidence of severe renal impairment (e.g., estimated glomerular filtration rate \\[eGFR\\] \\\u003C30 mL\u002Fmin\u002F1.73 m\\^2).\n5. Pregnant or lactating women.\n6. Patients with serum potassium level ≥5.5 mmol\u002FL at baseline.","ALL","18 Years","99 Years",{"count":39,"type":40},500,"ESTIMATED","OBSERVATIONAL","The aim of this study is to evaluate the real-world effectiveness of ARNi (sacubitril\u002Fvalsartan) therapy and antihypertensive monotherapy in reducing blood pressure in hypertensive patients residing in the United Arab Emirates. Antihypertensive monotherapies will include angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), and calcium channel blockers (CCBs).",[44],"Hypertension",[46,47,48],"Angiotensin Receptor-Neprilysin Inhibitor","Sacubitril\u002Fvalsartan","High blood pressure","NOT_YET_RECRUITING","2026-08-17",{"date":52,"type":53},"2026-08-19","ACTUAL",{"date":55,"type":40},"2026-08-15",{"date":57,"type":40},"2027-08-15",{"name":17,"class":6}]